Under construction – not a live service
Sign in
Not yet taking people in United StatesNo phase

A Skin Patch to Measure Sweat Chloride in Cystic Fibrosis

Compares a new sweat test patch with standard testing in cystic fibrosis.

Plain-language title generated from the registry record
Registry title: Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

Key facts

Where
Atlanta, United StatesSee the 2 sites

Where in United States

  • Adult Cystic Fibrosis ClinicAtlanta, United StatesNo longer taking part
  • Arthur M Blank Hospital - Children's Healthcare of AtlantaAtlanta, United StatesNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Emory University
Trial code
NCT07414810
Record updated
27 October 2026
Original description
This study is being done to test a device called micro Sweat Test Patch (mSTP or µSTP).Read full original descriptionShow less

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

This study is being done to test a device called micro Sweat Test Patch (mSTP or µSTP).

The study team will compare the standard of care (SOC) method of sweat testing with a novel sweat test technique using an integrated micro Sweat Test Patch (µSTP) with microneedle assembly made out of Pilocarpine nitrate, microfluidic channels, and a chloride sensor for point-of-care (POC) measurements of sweat chloride concentrations in newborns being evaluated for cystic fibrosis (CF) diagnosis and in pediatric and adult people with CF (pwCF).

The procedures involve performing a SOC sweat test (if they are not a neonate) and the novel sweat test developed by the research team.

Recruitment for the study will take place at Children's Healthcare of Atlanta and Emory Healthcare cystic fibrosis clinics.

Inclusion: Age 0-90 years old; Signed a written informed consent; Confirmed CF diagnosis via genetic test or elevated Immunoreactive Trypsinogen (IRT) level in newborn screen.

Exclusion: History of skin disorders (eczema, psoriasis, etc.) that could prevent sweat testing on the forearms.

ClinicalTrials.gov NCT07414810